NASDAQ:ENLV   Enlivex Therapeutics Ltd
Sepsis is currently the number three cause of death in the Western world, after heart-lung failure and cancer. This is a market of more than $ 30 billion.
The Enlv product was originally intended for the treatment of sepsis (sepsis) and is in 2nd place in drug trials. The drug developed by Enlv is supposed to over-activate the immune system in patients with infectious diseases whose condition is severe. In severe situations the immune system can lose control and get into a spin known as a cytokine storm and cause extensive damage to the body. Enlv has decided to expand product development in corona treatment as well, after it became clear that this virus could, in severe cases, cause a cytokine storm.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.